Japan Medical Dynamic Marketing, Inc. (7600) AI Stock Analysis

Japan Medical Dynamic Marketing, Inc.

(TSE/TYO:7600)

Select Model

Rating:33Underperform

Price Target:JPY 571.00▼(-1.21% Downside)

Action:downgraded

Date:09/09/26

The overall score is very low, driven primarily by extremely weak financial performance, particularly negative free cash flow and declining revenue. Technicals confirm a strong downtrend with the stock trading well below key moving averages. The negative P/E ratio further detracts from the valuation appeal, despite a modest dividend yield.

Positive Factors

Moderate LeverageModerate leverage gives the company more financial flexibility than a highly indebted structure would, helping it absorb operating volatility and fund necessary investment. Although debt has risen, the current debt-to-equity level remains manageable and does not by itself indicate balance-sheet stress.

Negative Factors

Revenue DeclineThe shift from strong growth in earlier years to a year-over-year revenue decline signals weaker demand, reduced distribution activity, or other operating pressure. Sustained top-line contraction would limit scale benefits, reduce resources available for investment, and make recovery in earnings more dependent on cost reductions.

Japan Medical Dynamic Marketing, Inc. (7600) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 15.23B
Dividend Yield: 2.94%
Average Volume (3M): 283.79K
Price to Earnings (P/E): -69.1
Beta (1Y): 0.90
Revenue Growth: -6.64%
EPS Growth: 67.08%
Country: Japan
Employees: 539
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model

Company Description

Japan Medical Dynamic Marketing, Inc. (JMDM) engages in the development, production, importation, and distribution of medical instruments throughout Japan and the United States. Its product portfolio features a variety of trauma devices, including su...

How the Company Makes Money

The company primarily generates revenue through the sale and distribution of medical devices and related healthcare products to customers such as hospitals, clinics, and other medical institutions. Revenue is typically recognized from product sales (...

Japan Medical Dynamic Marketing, Inc. Financial Statement Overview

Summary

Financial performance is weak. Revenue declined 4.3%, margins are thin (operating margin 2.4%), and cash flow is deeply negative with free cash flow at -¥1.76 billion. The income statement and cash flow scores are very low, offsetting a moderate balance sheet.

Income Statement

30Negative

Balance Sheet

42Neutral

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	23.32B	23.92B	25.11B	23.18B	21.31B	19.19B
Gross Profit	12.00B	12.74B	15.65B	14.76B	13.99B	12.99B
EBITDA	1.62B	2.19B	1.40B	3.27B	3.35B	4.21B
Net Income	-220.55M	263.14M	-461.80M	1.27B	1.42B	2.14B
Balance Sheet
Total Assets	35.38B	35.68B	33.83B	31.49B	29.43B	27.34B
Cash, Cash Equivalents and Short-Term Investments	2.56B	3.11B	3.18B	2.32B	2.80B	2.59B
Total Debt	6.63B	5.87B	3.29B	1.49B	1.87B	1.85B
Total Liabilities	10.55B	10.25B	9.09B	5.88B	6.14B	5.85B
Stockholders Equity	24.81B	25.40B	24.68B	25.51B	23.16B	21.39B
Cash Flow
Free Cash Flow	0	-1.75B	-504.10M	302.45M	870.67M	1.53B
Operating Cash Flow	0	205.55M	1.05B	2.10B	2.19B	3.11B
Investing Cash Flow	0	-2.00B	-1.67B	-1.80B	-1.48B	-1.75B
Financing Cash Flow	0	1.65B	1.49B	-840.71M	-514.78M	-1.29B

Japan Medical Dynamic Marketing, Inc. Technical Analysis

Technical Analysis SentimentNegative

Last Price578.00

Price Trends

50DMA669.86Negative

100DMA779.61Negative

200DMA673.57Negative

Market Momentum

MACD-23.66Negative

RSI32.66Neutral

STOCH11.12Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Negative. The current price of 578.00 is below the 20-day moving average (MA) of 613.60, below the 50-day MA of 669.86, and below the 200-day MA of 673.57, indicating a bearish trend. The MACD of -23.66 indicates Negative momentum. The RSI at 32.66 is Neutral, neither overbought nor oversold. The STOCH value of 11.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7600.

Japan Medical Dynamic Marketing, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

JP:7600 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:6678	82Outperform	JPY 18.42B	12.22	―	5.97%	20.88%	44.61%
JP:6849	61Neutral	JPY 265.01B	19.32	―	1.98%	1.43%	1.86%
JP:6523	58Neutral	JPY 180.17B	19.53	5.76%	2.97%	3.04%	-19.26%
JP:7779	56Neutral	JPY 40.54B	147.69	0.69%	―	-8.42%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
JP:4549	50Neutral	JPY 76.06B	41.05	―	2.51%	3.92%	-52.01%
JP:7600	33Underperform	JPY 15.22B	-69.06	―	2.94%	-6.64%	67.08%

* General Sector Average

Performance Comparison

JP:7600 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:7600	Japan Medical Dynamic Marketing, Inc.	578.00	115.01	24.84%
JP:7779	CYBERDYNE	192.00	16.00	9.09%
JP:6523	PHC Holdings Corp.	1415.00	438.88	44.96%
JP:4549	Eiken Chemical Co., Ltd.	2307.00	3.99	0.17%
JP:6678	Techno Medica Co., Ltd.	2161.00	335.34	18.37%
JP:6849	Nihon Kohden Corporation	1616.50	-129.90	-7.44%

Japan Medical Dynamic Marketing, Inc. Corporate Events

Japan Medical Dynamic Marketing Cuts U.S. Workforce to Bolster Profitability

Oct 15, 2026

Japan Medical Dynamic Marketing, Inc. has launched cost-cutting measures at its U.S. subsidiary Ortho Development Corporation, driven by declining net sales and the need to strengthen its earnings base. The subsidiary will undergo an organizational r...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 09, 2026

Japan Medical Dynamic Marketing, Inc. AI Stock Analysis